Literature DB >> 26865131

Dexmedetomidine post-treatment induces neuroprotection via activation of extracellular signal-regulated kinase in rats with subarachnoid haemorrhage.

Y Wang1, R Han2, Z Zuo3.   

Abstract

BACKGROUND: Dexmedetomidine, a sedative agent, provides neuroprotection when administered during or before brain ischaemia. This study was designed to determine whether dexmedetomidine post-treatment induces neuroprotection against subarachnoid haemorrhage (SAH) and the mechanisms for this effect.
METHODS: Subarachnoid haemorrhage was induced by endovascular perforation to the junction of the right middle and anterior cerebral arteries in adult rats. Dexmedetomidine was applied immediately or 2 h after onset of SAH. Neurological outcome was evaluated 2 days after SAH. Right frontal cortex area 1 was harvested 24 h after SAH for western blotting.
RESULTS: Subarachnoid haemorrhage reduced neurological scores and increased brain oedema and blood-brain barrier permeability. These effects were attenuated by dexmedetomidine post-treatment. Neuroprotection by dexmedetomidine was abolished by PD98095, an inhibitor of extracellular signal-regulated kinase (ERK) activation. Phospho-ERK, the activated form of ERK, was increased by dexmedetomidine; this activation was inhibited by PD98095.
CONCLUSIONS: Dexmedetomidine post-treatment provides neuroprotection against SAH. This effect appears to be mediated by ERK.
© The Author 2016. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  dexmedetomidine; extracellular signal-regulated kinase; post-treatment; subarachnoid haemorrhage

Mesh:

Substances:

Year:  2016        PMID: 26865131      PMCID: PMC4748945          DOI: 10.1093/bja/aev549

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  35 in total

1.  Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Reversal by the alpha 2-adrenergic antagonist atipamezole.

Authors:  W E Hoffman; E Kochs; C Werner; C Thomas; R F Albrecht
Journal:  Anesthesiology       Date:  1991-08       Impact factor: 7.892

Review 2.  Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review.

Authors:  J W Hop; G J Rinkel; A Algra; J van Gijn
Journal:  Stroke       Date:  1997-03       Impact factor: 7.914

3.  Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia.

Authors:  J Kuhmonen; J Pokorný; R Miettinen; A Haapalinna; J Jolkkonen; P Riekkinen; J Sivenius
Journal:  Anesthesiology       Date:  1997-08       Impact factor: 7.892

4.  Developmental age influences the effect of epidural dexmedetomidine on inflammatory hyperalgesia in rat pups.

Authors:  Suellen M Walker; Richard F Howard; Kevin A Keay; Maria Fitzgerald
Journal:  Anesthesiology       Date:  2005-06       Impact factor: 7.892

5.  Dexmedetomidine does not attenuate increases in excitatory amino acids after transient global ischemia in the rabbit.

Authors:  H K Kim; M H Zornow; M A Strnat; M Maze
Journal:  J Neurosurg Anesthesiol       Date:  1996-07       Impact factor: 3.956

6.  Dexmedetomidine-induced sedation does not mimic the neurobehavioral phenotypes of sleep in Sprague Dawley rat.

Authors:  Abigail G Garrity; Simhadri Botta; Stephanie B Lazar; Erin Swor; Giancarlo Vanini; Helen A Baghdoyan; Ralph Lydic
Journal:  Sleep       Date:  2015-01-01       Impact factor: 5.849

7.  Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation.

Authors:  J H Garcia; S Wagner; K F Liu; X J Hu
Journal:  Stroke       Date:  1995-04       Impact factor: 7.914

8.  Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia.

Authors:  C Maier; G K Steinberg; G H Sun; G T Zhi; M Maze
Journal:  Anesthesiology       Date:  1993-08       Impact factor: 7.892

9.  Has there been a decline in subarachnoid hemorrhage mortality?

Authors:  T J Ingall; J P Whisnant; D O Wiebers; W M O'Fallon
Journal:  Stroke       Date:  1989-06       Impact factor: 7.914

10.  Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype.

Authors:  Daqing Ma; Mahmuda Hossain; Nishanthan Rajakumaraswamy; Mubarik Arshad; Robert D Sanders; Nicholas P Franks; Mervyn Maze
Journal:  Eur J Pharmacol       Date:  2004-10-11       Impact factor: 4.432

View more
  14 in total

1.  Dexmedetomidine-induced neuroprotection: is it translational?

Authors:  Yunzhen Wang; Ruquan Han; Zhiyi Zuo
Journal:  Transl Perioper Pain Med       Date:  2016

2.  Dexmedetomidine alleviates inflammatory response and oxidative stress injury of vascular smooth muscle cell via α2AR/GSK-3β/MKP-1/NRF2 axis in intracranial aneurysm.

Authors:  Ze Zhang; Xiue Mu; Xiaohui Zhou
Journal:  BMC Pharmacol Toxicol       Date:  2022-10-23       Impact factor: 2.605

3.  Factors affecting successful use of intranasal dexmedetomidine: a cohort study from a national paediatrics tertiary centre.

Authors:  Lijia Fan; Yinghao Lim; Gloria Songmei Wong; Ryan Taylor
Journal:  Transl Pediatr       Date:  2021-04

4.  Dexmedetomidine: an attractive adjunct to anesthesia.

Authors:  Hong-Beom Bae
Journal:  Korean J Anesthesiol       Date:  2017-07-13

5.  The clinical effect of dexmedetomidine combined with parecoxib sodium on sedation, antianxiety and prevention of intubation stress in patients undergoing functional endoscopic sinus surgery: a randomised controlled trial.

Authors:  Xiaoxia Gu; Xiujuan Tan; Jinxian Chen; Jingjing Wang; Yue Lu; Liangqing Zhang
Journal:  BMC Anesthesiol       Date:  2020-07-06       Impact factor: 2.217

6.  The safety and efficacy of dexmedetomidine versus propofol for patients undergoing endovascular therapy for acute stroke: A prospective randomized control trial.

Authors:  Bin Wu; Hongping Hu; Ailan Cai; Chunguang Ren; Shengjie Liu
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

7.  Dexmedetomidine attenuates the neurotoxicity of propofol toward primary hippocampal neurons in vitro via Erk1/2/CREB/BDNF signaling pathways.

Authors:  Youbing Tu; Yubing Liang; Yong Xiao; Jing Lv; Ruicong Guan; Fei Xiao; Yubo Xie; Qiang Xiao
Journal:  Drug Des Devel Ther       Date:  2019-02-19       Impact factor: 4.162

8.  Dexmedetomidine: present and future directions.

Authors:  Seongheon Lee
Journal:  Korean J Anesthesiol       Date:  2019-06-21

9.  Effect of intraoperative infusion of dexmedetomidine on postoperative recovery in patients undergoing endovascular interventional therapies: A prospective, randomized, controlled trial.

Authors:  Chunguang Ren; Huiying Xu; Guangjun Xu; Lei Liu; Guoying Liu; Zongwang Zhang; Jun-Li Cao
Journal:  Brain Behav       Date:  2019-05-17       Impact factor: 2.708

Review 10.  Role of Anesthetics and Their Adjuvants in Neurovascular Protection in Secondary Brain Injury after Aneurysmal Subarachnoid Hemorrhage.

Authors:  Umeshkumar Athiraman; Gregory J Zipfel
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.